JCO Clin Cancer Inform. 2025 Aug;9:e2500018. doi: 10.1200/CCI-25-00018. Epub 2025 Aug 13.
ABSTRACT
PURPOSE: Breast cancer (BC) is a leading cause of morbidity and mortality among women. Symptoms and treatment-related side effects often go undetected during routine follow-ups. Digital health interventions offer promising tools for real-time monitoring and personalized care. We aimed to implement and evaluate the feasibility of a mobile health electronic Patient-Reported Outcomes (ePRO)-based platform for telemonitoring patients with BC undergoing (neo)adjuvant chemotherapy.
METHODS: This prospective observational study enrolled patients with BC (TNM stages I to III) initiating chemotherapy at Barretos Cancer Hospital in Brazil. Participants were telemonitored using the ThummiOnco platform for 4-6 months, following a standardized protocol. Feasibility was assessed through platform usage, resolution of patient-reported symptoms (according to Common Terminology Criteria for Adverse Events) within 48-72 hours, and health care outcomes, including additional consultations, dose reductions, treatment interruptions/discontinuations, hospitalizations, and mortality. Statistical analysis was performed using descriptive statistics.
RESULTS: Between October 2022 and June 2023, 67 eligible patients (median age 51 years) were included, with 62% receiving neoadjuvant chemotherapy. The median number of app accesses per patient was 38, with 6.65 daily symptom reports and 94% adherence. At 48 hours, 67% of patient-reported symptoms were fully resolved, whereas at 72 hours the resolution rate was 75.4%. Regarding resolution by grade, 83% of grade 1, 69.5% of grade 2, and 54.8% of grade 3 symptoms were fully resolved. Complementary consultations were needed for 34 patients. Dose reductions occurred in 10 (14.9%), treatment interruptions/discontinuations in 35 (52.2%), and hospitalizations in seven (10.4%). One patient died from progressive disease.
CONCLUSION: Telemonitoring facilitated early symptom identification and management. Most reports were resolved through the platform, with minimal additional demands on the health care team. Future studies should assess cost-effectiveness and scalability across diverse populations.
PMID:40802911 | DOI:10.1200/CCI-25-00018
